Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Non Operating Income (2021 - 2025)

Historic Non Operating Income for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to -$8.4 million.

  • Oncology Institute's Non Operating Income fell 27389.38% to -$8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.3 million, marking a year-over-year decrease of 25783.37%. This contributed to the annual value of -$4.5 million for FY2024, which is 2532.04% up from last year.
  • Oncology Institute's Non Operating Income amounted to -$8.4 million in Q3 2025, which was down 27389.38% from -$5.9 million recorded in Q2 2025.
  • Oncology Institute's 5-year Non Operating Income high stood at $37.9 million for Q1 2022, and its period low was -$9.7 million during Q1 2025.
  • Moreover, its 5-year median value for Non Operating Income was $54000.0 (2021), whereas its average is $4.3 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first soared by 3212037.04% in 2022, then tumbled by 76994.35% in 2025.
  • Quarter analysis of 5 years shows Oncology Institute's Non Operating Income stood at $28.2 million in 2021, then plummeted by 51.41% to $13.7 million in 2022, then tumbled by 127.58% to -$3.8 million in 2023, then surged by 66.85% to -$1.3 million in 2024, then plummeted by 574.38% to -$8.4 million in 2025.
  • Its Non Operating Income stands at -$8.4 million for Q3 2025, versus -$5.9 million for Q2 2025 and -$9.7 million for Q1 2025.